Trial Profile
A Phase II, Open-label, Multicentre, Pharmacokinetic, Pharmacodynamics and Safety Study of a New Paediatric Eurartesim Dispersible Formulation and Crushed Film Coated Eurartesim Tablet, in Infant Patients With P. Falciparum Malaria
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Oct 2017
Price :
$35
*
At a glance
- Drugs Dihydroartemisinin/piperaquine (Primary)
- Indications Falciparum malaria
- Focus Pharmacokinetics
- Sponsors sigma-tau SpA
- 23 Oct 2017 Primary endpoint (PCR-corrected Adequate Clinical and Parasitological Response (ACPR), dispersible tablet formulation of DHA/PQP Vs crushed tablet) has been met as per the results published in the Antimicrobial Agents and Chemotherapy
- 23 Oct 2017 Results published in the Antimicrobial Agents and Chemotherapy
- 08 Jul 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.